Abstract
Overexpression of P-glycoprotein (Pgp) is associated with multidrug resistance (MDR) of tumor cells to a number of chemotherapeutic drugs. Pgp inhibitors have been shown to effectively reverse Pgp-mediated MDR. We prepared a series of phenoxy-N-phenylacetamide derivatives and tested for their ability to inhibit Pgp as potential MDR reversing agents, using a Pgp over-expressing MCF-7/ADR cell line. Some of the synthesized compounds exhibited moderate to potent reversal activity. Of note, compound 4o showed a 3.0-fold increased inhibition compared with verapamil, a well-known Pgp inhibitor. In addition, co-treatment of the representative compound 4o and a substrate anticancer agent doxorubicin resulted in a remarkable increase in doxorubicin's antitumor effect and inhibition of DNA synthesis in the MCF-7/ADR cell line. Taken together, these findings suggest that compound 4o could be a useful lead for development of a novel Pgp inhibitor for treatment of MDR.
Original language | English |
---|---|
Pages (from-to) | 3666-3674 |
Number of pages | 9 |
Journal | Bulletin of the Korean Chemical Society |
Volume | 32 |
Issue number | 10 |
DOIs | |
State | Published - 20 Oct 2011 |
Keywords
- Chemotherapy
- MDR reversal activity
- Pgp
- Phenoxy-N-phenylacetamide derivatives